What the FDA labels say about taking them together
Atazanavir and dihydroergotamine
Atazanavir's FDA label of August 6, 2025 names dihydroergotamine in its contraindications section; the dihydroergotamine labels PlainMeds reads (4) do not name atazanavir. The atazanavir label: “Coadministration of REYATAZ with ergot derivatives is contraindicated. This is due to the potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and …”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals).
What does the atazanavir label say about dihydroergotamine?
Atazanavir label, contraindicationsDrug Class: Ergot Derivatives; Drugs within class that are contraindicated with atazanavir capsules: Dihydroergotamine, ergonovine, ergotamine, methylergonovine
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: Ergot derivatives: dihydroergotamine, ergotamine, ergonovine, methylergonovine; Effect on Concentration of Atazanavir or Concomitant Drug: ↑ ergot derivatives; Clinical Comment: Coadministration of atazanavir with ergot derivatives is contraindicated. This is due to the potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues [see ].
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the dihydroergotamine label say about atazanavir?
Dihydroergotamine's label (effective March 6, 2025) and its 3 other brand-application labels do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Dihydroergotamine | |
|---|---|---|
| Labeled for | HIV | Migraine |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $29.44 per mL 4 mg/mL nasal spray |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once